Clinical trial NCT05226923: Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
Official title: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bacterial Infections
Keywords: Bacterial Disease
Bacterial Infection
Bacterial Infections
Bacterial
Healthy Volunteers
Lead sponsor: Sumitovant Biopharma, Inc.
Sponsor class: INDUSTRY
First posted: 2022-02-07
Enrollment: 123
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study is a first-in-human, Phase 1, randomized, double- blind, four-part, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of single (Part 1) and repeat (Part 2) escalating intravenous doses of KSP-1007. Repeated escalating doses of KSP-1007 will be co-administered with meropenem (Part 3) and single, ascending doses of KSP-1007 will be administered alone in healthy Japanese subjects (Part 4)

Detailed description: Carbapenem-resistant Gram-negative bacteria are responsible for serious, life-threatening infections and are regarded as an urgent threat by the Centers for Disease Control and Prevention and the World Health Organizations. One principal mechanism of carbapenem resistance is bacterial production of carbapenemases, which reduce the effectiveness of meropenem and other carbapenem class antibiotics. Sumitovant Biopharma is developing a fixed combination of meropenem and KSP-1007 for the treatment of serious bacterial infections.

Eligibility criteria: Inclusion Criteria:

* Healthy male or female subjects 18 to 55 years of age, inclusive
* Females that engage in heterosexual activity must agree to use a highly selective birth control (BC) method (\< 1% failure rate per year) throughout the study, or have a documented reproductive status of non-childbearing based on medical history, or is postmenopausal
* Males that engage in heterosexual activity that has the risk of pregnancy must agree to use effective BC and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication
* Body mass index (BMI) 2: 18 kg/m2 and :s 32 kg/m2

Exclusion Criteria:

* History of Gilbert's Syndrome
* History of severe allergic reactions to β-lactams or β-lactamase inhibitors or a history allergic reactions to multiple medications.
* Pregnant female, determined by positive serum or urine human chorionic gonadotropin pregnancy test at Screening, or prior to dosing
* Lactating female
* Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at Screening) of \> 499 mL within 56 days prior to Day 1
* Participation in a study with an investigational drug or device study with last dose of investigational drug within 30 days (90 days if the study involved a biologic, cellular, or vaccine product) or 5 half-lives, whichever is longer, before study treatment administration
* Subjects with abnormal hepatic and/or renal function, that could interfere with the metabolism, and/or excretion of the study treatments
* Abnormal blood pressure, either low (defined as \< 90 mmHg systolic and/ or \< 45 mmHg diastolic) or high (defined as \> 140 mmHg systolic and/ or \> 90 mmHg diastolic) at Screening
* Positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV at Screening. Subjects who test positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg) also will be ineligible. Evidence of prior HBV vaccination (positive hepatitis B surface antibody \[HBsAb)) is not exclusionary.
* Subjects unable to abstain from alcohol for 48 hours prior to admission through to completion of the Follow-up visit

Primary outcomes:
measure: Incidence of adverse events assessed by subject .
timeFrame: up to Day 14
Secondary outcomes:
measure: Peak plasma concentration of KSP-1007
timeFrame: Up to 5 days after dosing
measure: Plasma concentration of KSP-1007 versus time curve
timeFrame: Up to 5 days after dosing
measure: Cumulative amount of KSP-1007 excreted in urine over time
timeFrame: Up to 5 days after start of dosing
measure: Renal clearance of KSP-1007 in urine over time
timeFrame: Up to 5 days after start of dosing
measure: Peak plasma concentration of meropenem
timeFrame: Up to 5 days after start of dosing
measure: Plasma concentration versus time curve of meropenem
timeFrame: Up to 5 days after start of dosing
measure: Cumulative amount of meropenem excreted in urine over time
timeFrame: Up to 5 days after start of dosing
measure: Renal clearance of meropenem in urine over time
timeFrame: Up to 5 days after start of dosing
measure: ECG QTcF interval
timeFrame: 24 hours after start of dosing
Other outcomes:
Locations:
city: Lenexa
country: United States
facility: PRA Health Sciences
state: Kansas
Study officials:
affiliation: Sumitovant Biopharma, Inc.
name: Hayes Dansky, M.D.
role: STUDY_DIRECTOR
References: